TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Last trade$62.82
Day change+$0.055 (+0.09%)
Day range$61.58 – $63.43
Volume807,256
Market cap$9.49B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$9.49B
Price / earnings
89.44×
Price / book
16.58×
Price / sales
10.57×
EV / sales
10.92×
EV / EBITDA
50.81×
Profitability
Earnings per share
$0.70
Return on assets
6.66%
Return on equity
18.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.3×
Current ratio
4.5×
Quick ratio
3.75×
Cash ratio
1.65×
Cash flow
Price / cash flow
109.98×
Price / free cash flow
110.87×
Free cash flow
$85.56M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TGTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$259.94M
$240.34M
$204.92M
$192.57M
$161.71M
$141.15M
$120.86M
$108.19M
Cost of revenue
$42.08M
$41.19M
$33.51M
$38.14M
$28.09M
$18.94M
$15.54M
$15.4M
Gross profit
$217.86M
$199.14M
$171.41M
$154.43M
$133.62M
$122.21M
$105.32M
$92.79M
Selling, general and administrative
$88.22M
$90.2M
$19.95M
$28.64M
$68.71M
$59.9M
$14.97M
$19.95M
Research and development
$43.74M
$87.27M
$43.52M
$24.58M
$35.54M
$27.46M
$43.03M
$12.71M
Total operating expenses
$131.96M
$177.47M
$136.61M
$103.94M
$104.25M
$87.37M
$96.69M
$62.84M
Operating income
$85.9M
$21.67M
$34.8M
$50.49M
$29.37M
$34.84M
$8.62M
$29.95M
Interest expense
-$15.82M
-$16.57M
-$7.67M
-$6.53M
-$6.72M
-$6.72M
-$6.76M
-$7.06M
Income before taxes
$73.86M
$10.23M
$20.36M
$45.09M
$25.91M
$30.92M
$5.47M
$25.45M
Income taxes
$18.4M
$2.45M
$586K
$22.06M
-$364.99M
$2.73M
$408K
$2.12M
Net income
$55.46M
$7.78M
$19.78M
$23.04M
$390.9M
$28.19M
$5.06M
$23.33M
Net income attributable to common shareholders
$55.46M
$7.78M
$19.78M
$23.04M
$390.9M
$28.19M
$5.06M
$23.33M
EBITDA
$85.97M
$21.73M
$34.83M
$50.38M
$29.38M
$34.86M
$8.63M
$29.8M
Basic earnings per share
$0.39
$0.05
$0.14
$0.17
$2.69
$0.19
$0.03
$0.16
Diluted earnings per share
$0.35
$0.05
$0.12
$0.14
$2.43
$0.17
$0.03
$0.13
Recent news
Company coverage with links to the original publishers.
Zacks highlights four commercial-stage biotechnology companies demonstrating strong revenue growth and market penetration: TG Therapeutics (Briumvi for MS), BioCryst Pharmaceuticals (Orladeyo for HAE), Insmed (Brinsupri and Arikayce for respiratory diseases), and Madrigal Pharmaceuticals (Rezdiffra for MASH). All four companies show consistent quarterly sales increases, expanding patient adoption, and strategic initiatives to broaden their commercial reach through new formulations, international expansion, and label expansions.
TG Therapeutics reported Q3 2026 EPS of 35 cents and revenues of $259.9 million, both beating consensus estimates. Briumvi U.S. sales surged 52% to $232.6 million driven by physician adoption and patient growth. The company raised its 2026 global revenue guidance to $1 billion and expects Q4 U.S. Briumvi sales above $260 million. The stock rose 5.9% following the results.
ImmunityBio reported a Q3 adjusted loss of 10 cents per share, exceeding estimates of 8 cents, with total revenues of $48.8 million missing consensus of $61 million. While Anktiva revenues grew 53% year-over-year to $48.7 million, they declined 4% sequentially, ending eight quarters of consecutive growth and raising concerns about sales momentum. The FDA expanded Anktiva's label to cover all BCG-unresponsive NMIBC patients, and the company received approval in Israel, supporting future growth prospects.
Several companies reported better-than-expected third-quarter 2026 earnings results, driving positive stock movements. KKR & Co. beat estimates with $1.78 EPS vs. $1.58 expected, NRG Energy surged 10.3% with $4.68 EPS vs. $3.44 expected, TG Therapeutics rose 5.9% with $0.35 EPS vs. $0.28 expected, and Affiliated Managers Group gained 5.6% with $9.5 EPS vs. $8.7 expected.
TG Therapeutics (TGTX) reported Q3 2026 earnings of $0.35 per share, beating consensus estimates of $0.28, with revenues of $259.94 million exceeding expectations by 5.17%. The stock has gained 100.7% year-to-date and received a Zacks Rank #1 (Strong Buy) rating based on favorable estimate revisions. The company's Medical - Biomedical and Genetics industry ranks in the top 43% of Zacks industries.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.